Key Points
- CFO Christopher Ryan Sullivan sold 10,185 Avalo Therapeutics shares at an average price of $17.62, generating $179,459.70. The Rule 10b5-1 transaction reduced his ownership by 20.34%, leaving him with 39,900 shares.
- Avalo shares opened at $16.12 after falling 6.2%, with the stock trading below its 50-day average. The company reported a quarterly loss of $0.83 per share, missing analyst expectations of a $0.58 loss.
- Institutional investors own 87.06% of the company, while analysts maintain a generally positive outlook: 12 rate the stock Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $45.10.
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Sullivan sold 10,185 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $17.62, for a total value of $179,459.70. Following the completion of the transaction, the chief financial officer owned 39,900 shares of the company's stock, valued at $703,038. The trade was a 20.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Avalo Therapeutics Stock Down 6.2%
NASDAQ AVTX opened at $16.12 on Friday. The company has a 50-day simple moving average of $19.07 and a two-hundred day simple moving average of $17.05. Avalo Therapeutics, Inc. has a 12-month low of $9.54 and a 12-month high of $24.27. The firm has a market cap of $864.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.78.
Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.25). Equities analysts expect that Avalo Therapeutics, Inc. will post -2.69 earnings per share for the current fiscal year.
Institutional Trading of Avalo Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics during the second quarter valued at about $56,000. Dimensional Fund Advisors LP purchased a new stake in Avalo Therapeutics during the 3rd quarter valued at approximately $143,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics in the 1st quarter valued at $174,000. California State Teachers Retirement System bought a new stake in shares of Avalo Therapeutics in the second quarter worth about $196,000. Finally, Jump Financial LLC bought a new stake in Avalo Therapeutics in the 4th quarter worth approximately $238,000. 87.06% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have issued reports on AVTX shares. HC Wainwright reduced their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They set an "outperform" rating and a $38.00 target price on the stock. Weiss Ratings upgraded shares of Avalo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of Avalo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $45.10.
View Our Latest Analysis on AVTX
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
